Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salbutamol exposure and persistent pulmonary hypertension in newborns
2020-003913-36Phase 3Active
- Sponsor
- Medical University of Warsaw
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of salbutamol in transient tachypnea of the newborn (TTN) and persistent pulmonary hypertension of the newborn (PPHN) (2 arms), sponsored by Medical University of Warsaw. Primary endpoint: Incidence of persistent pulmonary hypertension of the newborn. Started Dec 2020; status: active.
02
Drugs
salbutamol
03
Conditions
transient tachypnea of the newborn (TTN)persistent pulmonary hypertension of the newborn (PPHN)
Beyond the preview
Go deeper on 2020-003913-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003913-36.